Published: May 23, 2018

The Sunnybrook Health Sciences Centre and the Ottawa Hospital are currently enrolling women in the Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare conventional mammography (2-D) to the newer digital tomosynthesis method (3-D). Although 3-D mammography, being the newer technology, is likely to detect more findings that require follow-up, it is also likely to lead to more procedures and treatments.

Published: March 28, 2018

Dr. Frances Shepherd, medical oncologist at Princess Margaret Cancer Centre, has received the prestigious 2018 Canada Gairdner Wightman Award "for her global leadership in oncology which has contributed significantly to the improving survival outcome of lung cancer patients worldwide."

Published: March 15, 2018
(left to right) Shakeel Virk, Director Operations & Pathology Coordinator of the CCTG Tumour Tissue Data Repository, Dr David LeBrun, Academic Director, Queen's Laboratory for Molecular Pathology, Ms. Sophie Kiwala, MPP for Kingston and the Islands, Dr Lois Shepherd Director of the CCTG Tumour Tissue Data Repository, Dr. Madhuri Koti, Queen's University (back) Dr. John Fisher, Vice-Principal (Research), Queen’s University.
Published: January 08, 2018
Cancer Research Institute and Canadian Cancer Trials Group Announce Strategic Collaboration; ?>

CCTG and CRI collaborate to bring important improvements in cancer therapies to the patients that need them

The Cancer Research Institute (CRI) and the Canadian Cancer Trials Group (CCTG) have announced a multi-year collaboration to develop and conduct clinical trials in immunotherapy.

Published: January 02, 2018
CCTG network researchers have been recognized with the Order of Canada

CCTG network researchers have been recognized by Governor General Julie Payette who announced the Order of Canada appointments on Friday, Dec. 29. Please join us in congratulating Dr. Pritchard, Dr. Gleave and Dr. Eisenhauer on this wonderful honour and for their outstanding contributions to cancer clinical trial research in Canada.

Dr. Elizabeth Eisenhauer, Officer of the Order of Canada

Published: December 05, 2016
CCTG Directors -Dr. Elizabeth Eisenhauer, head of the Queen’s Department of Oncology, Dr. Joe Pater, former CCTG Director, Dr. Janet Dancey, CCTG Director,; ?>

Dr. Elizabeth Eisenhauer, head of the Queen’s Department of Oncology, Dr. Joe Pater, former CCTG Director, Dr. Janet Dancey, CCTG Director,

Patients facing a cancer diagnosis invariably have many questions, but one tops the list – what is the best treatment? Answering that question is the compelling goal of medical research that is testing new treatments for similarly-diagnosed patients in carefully monitored and controlled ways. Such studies, known as clinical trials, have been instrumental in altering and improving the way cancer is now approached.

Published: November 06, 2017
Judy’s volunteer work over the past twelve years has evolved into supporting the patient voice in clinical trials research

The Canadian Cancer Research Alliance (CCRA) has honored members of the research community for their leadership and significant contributions to cancer research in Canada. This year, two new awards have been introduced recognizing exceptional leadership in patient involvement in cancer research.

Published: September 25, 2017
Pancreatic cancer patient Susan Stewart with her family, she enrolled in the CCTG PA.7 immunotherapy and chemotherapy trial  ; ?>

Pancreatic cancer patient Susan Stewart shown here on the right with her family is
enrolled in the CCTG PA.7 immunotherapy and chemotherapy trial

An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer – the deadliest cancer facing Canadians today.

Published: September 06, 2017
 Dr Wendy  R.  Parulekar,  Senior  Investigator  at   CCTG; ?>
Dr. Wendy R. Parulekar, Senior Investigator MA.39

One of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. A new study undertaken by the Canadian Cancer Trials Group (CCTG) will look at whether additional radiation therapy is beneficial for patients with a specific subtype of breast cancer called luminal A.

Published: August 15, 2017
Dr. Janet Dancey, CCTG Director and JELF award recipient

The Canadian Foundation for Innovation (CFI) John R. Evans Leaders Fund (JELF) has announced a funding award of $197,065 to allow the Canadian Cancer Trials Group (CCTG) to acquire a state-of-the-art digital histology slide scanner.